AI software company Faro Health has partnered with biotechnology company Recursion to optimise and accelerate clinical protocol design for Recursion’s portfolio of clinical-stage drug candidates.
“To truly create better medicines for patients, we must place equal emphasis on leveraging data-driven and AI-powered solutions across both discovery and development,” said Recursion’s chief R&D officer and chief commercial officer Dr Najat Khan.
“At Recursion, we are committed to reimagining the entire process, and our partnership with Faro Health is a critical step in accelerating that vision.
Recursion, which decodes biology to industrialise drug discovery, will use Faro’s software to advance the protocol design of multiple upcoming clinical studies.
To learn more: Recursion and Faro Health partner to optimise clinical protocol design
